AU2019370999A1 - Novel agonistic anti TNFR2 antibody molecules - Google Patents

Novel agonistic anti TNFR2 antibody molecules Download PDF

Info

Publication number
AU2019370999A1
AU2019370999A1 AU2019370999A AU2019370999A AU2019370999A1 AU 2019370999 A1 AU2019370999 A1 AU 2019370999A1 AU 2019370999 A AU2019370999 A AU 2019370999A AU 2019370999 A AU2019370999 A AU 2019370999A AU 2019370999 A1 AU2019370999 A1 AU 2019370999A1
Authority
AU
Australia
Prior art keywords
antibody molecule
seq
antibody
tnfr2
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019370999A
Other languages
English (en)
Inventor
Björn FRENDÉUS
Petra Holmkvist
Linda MÅRTENSSON
Monika SEMMRICH
Ingrid Teige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of AU2019370999A1 publication Critical patent/AU2019370999A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019370999A 2018-11-01 2019-11-01 Novel agonistic anti TNFR2 antibody molecules Pending AU2019370999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18203996 2018-11-01
EP18203996.6 2018-11-01
PCT/EP2019/080003 WO2020089473A2 (en) 2018-11-01 2019-11-01 Novel agonistic antibody molecules

Publications (1)

Publication Number Publication Date
AU2019370999A1 true AU2019370999A1 (en) 2021-05-20

Family

ID=64109795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019370999A Pending AU2019370999A1 (en) 2018-11-01 2019-11-01 Novel agonistic anti TNFR2 antibody molecules

Country Status (11)

Country Link
US (2) US12139547B2 (https=)
EP (1) EP3873935A2 (https=)
JP (1) JP7664833B2 (https=)
KR (1) KR20210087466A (https=)
CN (3) CN121248780A (https=)
AU (1) AU2019370999A1 (https=)
BR (1) BR112021008007A2 (https=)
CA (1) CA3117756A1 (https=)
IL (1) IL282713A (https=)
MX (2) MX2021005151A (https=)
WO (1) WO2020089473A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220193196A1 (en) * 2019-05-28 2022-06-23 The Walter And Eliza Hall Institute Of Medical Research Methods for Modulating T Cell Activation
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合ｔｎｆｒ２的抗體及其用途
KR20230034367A (ko) * 2020-07-02 2023-03-09 바이오로직 디자인 리미티드 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도
EP4067381A1 (en) * 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
CN117836325A (zh) * 2021-06-22 2024-04-05 盛禾(中国)生物制药有限公司 一种抗tnfr2抗体及其制备方法和应用
CN115925929A (zh) 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
CA3256751A1 (en) * 2022-05-26 2023-11-30 Pfizer Inc. Anti-TNFR2 antibodies and their methods of use
JP2026503077A (ja) * 2023-01-09 2026-01-27 オデッセイ セラピューティクス，インコーポレイテッド 抗ｔｎｆｒ２抗原結合タンパク質及びその使用
CN121013905A (zh) * 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 已经引入至编码特异性结合于TNFR2的Stefin A蛋白变体或包括该蛋白变体的融合蛋白的核酸中的基因修饰的细胞，及其用途
WO2025250701A1 (en) * 2024-05-28 2025-12-04 Nektar Therapeutics Anti-tumor necrosis factor receptor 2 (tnfr2) antibodies and methods of use
WO2026022721A1 (en) * 2024-07-26 2026-01-29 Janssen Biotech, Inc. Anti-tnfr2 antibodies
CN119591710B (zh) * 2024-11-12 2026-01-13 澳门大学 一种激动性tnfr2单域抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN115043943A (zh) * 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US11859002B2 (en) * 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Also Published As

Publication number Publication date
JP7664833B2 (ja) 2025-04-18
JP2022514179A (ja) 2022-02-10
US20250066492A1 (en) 2025-02-27
MX2021005151A (es) 2021-07-15
US12139547B2 (en) 2024-11-12
US20220002426A1 (en) 2022-01-06
MX2025014435A (es) 2026-01-07
IL282713A (en) 2021-06-30
BR112021008007A2 (pt) 2021-08-10
KR20210087466A (ko) 2021-07-12
CA3117756A1 (en) 2020-05-07
CN121248781A (zh) 2026-01-02
WO2020089473A2 (en) 2020-05-07
WO2020089473A9 (en) 2020-10-01
CN112996812A (zh) 2021-06-18
CN121248780A (zh) 2026-01-02
CN112996812B (zh) 2025-09-12
WO2020089473A3 (en) 2020-07-16
EP3873935A2 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
US20250066492A1 (en) Agonistic anti tnfr2 antibody molecules
US11746148B2 (en) Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
KR102341926B1 (ko) 항-ox40 항체 및 이의 용도
US20250388690A1 (en) Novel antagonistic anti-tnfr2 antibodies
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN110869388A (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
WO2019184909A1 (zh) 新型抗体分子、其制备方法及其用途
CA3182362A1 (en) Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
RU2840049C9 (ru) Новые молекулы агонистических анти-tnfr2 антител
RU2840049C2 (ru) Новые молекулы агонистических анти-tnfr2 антител
HK40129120A (zh) 新颖激动性抗tnfr2抗体分子
HK40128816A (zh) 新颖激动性抗tnfr2抗体分子
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40109442A (zh) 新型拮抗性抗tnfr2抗体分子
HK40050308A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40050308B (zh) 新型拮抗性抗tnfr2抗体分子
HK40053328B (zh) 新颖激动性抗tnfr2抗体分子
HK40053328A (en) Novel agonistic anti tnfr2 antibody molecules